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Abstract
Determination of Antibiotic Release from Electrospun Nanofibers
by John Patrick O’Brien III
Decreasing the risk of infection following surgery for traumatic bone breaks is a major
focus of the medical and scientific community. Drug delivery devices are emerging as
powerful solutions for combating infection following these procedures. Current devices,
however, suffer several drawbacks including poor antibiotic release rate and control the
devices themselves not being biodegradable. This thesis studies the in vitro release rate
for antibiotics tobramycin and vancomycin from a biodegradable medical implant. Antibi-
otics, collagen, and bone growth factors are incorporated into Poly(lactide-co-glycolide)-
based electrospun nanofibers by local company eSpin for development. The drug-loaded
nanofibers are immersed in phosphate buffered saline (PBS) at 37◦ C and assayed at
specific time intervals to monitor antibiotic elution rate. The high concentration of phos-
phate and inorganic salts in PBS require a clean up step before quantification using
ultra performance liquid chromatography tandem mass spectrometry. Several methods
for clean-up are examined, including: dialysis, liquid-liquid extraction, and three solid
phase extractions. While no single method successfully extracted both antibiotics from
the PBS matrix, this survey of methods provides direction for future work in developing
this novel drug delivery device.
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Chapter 1
Introduction and Background
1.1 Infection Management
Despite many medical advances over the last century, infections remain a major problem
following some surgical procedures [1, 2]. Currently, the largest contributor for patient
readmissions following surgery is infection [3]. Despite realizing the threat of infection,
current medical practices lack definitive methods for controlling release location and con-
centration of antibiotics [2, 4]. To address this problem, many research labs are working on
projects ranging from elucidating the biochemical mechanism of antibiotics to engineering
novel devices for drug delivery. When antibiotics are supplied systemically, degradation
can start before the drugs have a chance to reach their intended areas. To compensate
for these inherent losses, initial antibiotic concentrations are increased towards levels ap-
proaching toxicity. Many groups are addressing this problem by developing drug delivery
devices that will allow for controlled antibiotic release directly to regions facing risk of
1
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infection. Interest in developing drug delivery devices has increased as their functional-
ity and characteristics have become better known. Of particular interest are biomedical
devices and biomaterials that can be placed local to high-risk or infected areas and are
biodegradable. Areas with deep tissue or bone, where the body struggles to regulate
blood flow in the event of trauma, are of particular interest to these research groups [4].
1.2 Drug Delivery Devices
Traumatic bone breaks often require surgery to reset the bone in place. Recovery from
these types of procedures are complicated by infections, a common occurrence for a region
experiencing severe trauma and a lack of nutrient flow. The risk of infection is greatest
during the period directly following surgery. To combat the risk of infection, current
medical procedure involves utilizing anti-microbial beads to release antibiotics to the at
risk region [5–7]. These beads are typically made of polymethylmethacrylate, and are
attached along a wire and implanted along the wound to locally deliver antibiotics during
recovery. Unfortunately, the wire-bead apparatus is not biodegradable, and a second
procedure is required to remove the beads from the body. The second operation, while
minor in nature, still allows for the possibility of complications to occur and delay the
recovery process. In addition, antibiotic elution is highly variable and control of antibiotic
release is minimal [2].
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1.3 Project Goals
The complications associated with the anti-microbial beads are leading research into
novel drug-delivery methods. There is on-going research involving UTC, UTCOM, and
local business eSpin to develop a device that mitigates the current problems with the
anti-microbial bead method; specifically, antibiotic elution control and biodegradability.
Advances in the field of nanotechnology have allowed eSpin to develop biodegradable,
biocompatible nanofibers that can release antibiotics as the fiber degrades. The elution
of therapeutically relevant concentrations of antibiotics at specific time points during the
recovery process is critical for proper infection management. In addition to antibiotics,
type-I collagen and bone growth factors are also incorporated into the nanofiber during
the spinning process. This project aims to develop a robust method for determining the
antibiotic elution rate of the nanofibers.
1.4 Nanofiber Composition
1.4.1 Polymer Scaffold
The fiber itself is a polymer of repeating lactic and glycolic acid molecules. The ratio of
lactic to glycolic acid in the polymer is an experimental variable that affects the stability
of the fiber and its rate of degradation [8, 9]. The poly(lactide-co-glycolide) (PLGA) elec-
trospun nanofiber scaffold degrades through hydrolysis of the ester bond of the polymer
chain to produce lactic and glycolic acid. As the polymer degrades the local environment
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becomes increasingly acidic. Unless the system is effectively buffered the acidic environ-
ment increases the rate of hydrolysis and degradation. The phenomenon of increased
self-degradation is known as autocatalysis [10].
IThere are three distinct phases of antibiotic release. The first phase involves the
molecules attached to the outer membrane of the scaffold. These molecules release from
the fiber as a function of their solubility in the body matrix and the flow surrounding the
fiber itself. The time period immediately following surgery is perhaps the most critical for
staving off infection, and requires a large local concentration of antibiotics for successful
protection. The goal of the first period of release is a large spike in antibiotic concentration
that surpasses the minimum concentration needed to inhibit infection. The second phase
of drug release occurs once degradation of the fiber begins. During this period, the
antibiotics diffuse into the surrounding environment as the nanofiber degrades [11]. This
period of recovery calls for uniform release of antibiotics to continue the fight against
infection, although the concentration does not need to be as high as the initial period. The
third phase occurs as the last of the fiber degrades into the body and the concentration
of antibiotics local to the surgery site slowly wanes until there is no longer any antibiotic
release.
1.4.2 Antibiotics
Two antibiotics are incorporated into the nanofiber mesh for infection control: tobramycin
and vancomycin. Tobramycin belongs to a family of antibiotics called aminoglycosides,
which are characterized by polarity and basicity [12–16]. The exact molecular weight of
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tobramycin is 467.25 amu. In terms of chemically relevant functional groups, tobramycin
has five primary amines that contribute to its basicity. The relative pKas of the to-
bramycin amino groups range from 5.7-9.3 [17]; the range of values is primarily driven
from interactions between the hydroxyl groups on the sugar rings and the amino groups
[18]. At physiological pH (7.4), tobramycin exists as a +5 charged molecular species.
Tobramycin is a common antibiotic used to treat gram negative bacteria, although it has
efficacy against some gram positive strains of bacteria as well [13, 14, 16]. Figure 1.1
displays the chemical structure of tobramycin, with key pKa values labeled.
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Figure 1.1: Chemical structure of tobramycin with pKa values of five amine groups
labeled.
Vancomycin belongs to the glycopeptide drug family, and is included in the fiber
to treat the gram positive bacteria tobramycin is ineffective against. Vancomycin differs
from tobramycin in several ways, including size, functional groups and molecular charge
at physiological pH. Vancomycin is significantly larger than Tobramycin, with an exact
molecular weight of 1447.43 amu. While tobramycin is characterized by its basic amine
groups, vancomycin contains a carboxylic acid group, three phenolic hydroxyl groups,
seven amide groups, one primary amine and one secondary amine that contribute to both
basic and acidic properties [7]. Figure 1.2 presents the chemical structure of vancomycin.
With varying acidic and basic functional groups (pKas ranging from 2.66-11.81) [19],
vancomycins molecular charge is strongly influenced by the local environment. At phys-
iological pH, vancomycin has a net charge of +1. Despite their differences, tobramycin
and vancomycin are both polar and hydrophilic.
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Figure 1.2: Chemical structure of vancomycin
At this time I would like to make a note on the novelty of this project. Many
determinations of antibiotic concentrations work with solely one family of antibiotics
where the range of analytes all share defining characteristics. This study aims to quantify
two very distinct antibiotics with one method.
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1.4.3 Collagen
Collagen is included in the nanofiber scaffold for several reasons. First and foremost,
collagen is very stable and adds rigidity to the nanofiber mesh. Part of collagens stability
can be attributed to its complex secondary and tertiary structure [4]. Collagens lin-
ear amino acid sequence has propensity to form alpha-helices in physiological solutions.
Three of these helices come together to form a triple-helix representative of collagens
tertiary structure. These triple-helices aggregate and form crosslinks that further add
to stability [4]. Another reason collagen is included is due to its biocompatibility and
natural abundance in the body. Type I Collagen composes 90% of extracellular protein
[20]. Despite its rigidity, collagen still allows for the quick release of antibiotics. Wachol-
Drewek et al (1996) showed a collagen sponge loaded with vancomycin released 99.9% of
the antibiotic in two days [21]. Collagen porosity and density represent further variables
for the spinning procedure, and has already been evaluated for its effect on elution rates
of antibiotics when incorporated with PLGA [22].
1.4.4 Bone Growth Factors
Bone morphogenetic proteins (BMPs) will also be spun in the nanofiber. BMPs have
been shown to increase bone recovery rates by increasing recruitment of mesenchymal cell
recruitment and differentiation, especially when combined with osteoconductive devices
[4, 23, 24]. The combination of BMPs and structural support from the nanofiber scaffold
will aid the recovery process complete and completed faster than existing methods.
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1.5 Instrumental Technique
With the optimal elution characteristics in mind, this project aimed to develop a method
of quantifying antibiotic release rate as a function of time, thus providing feedback for
device development. While the detailed nanofiber elution methodology is outlined in
Chapter 2, the general method is outlined below. Nanofiber samples were immersed
in 10.0 mL of a phosphate buffered saline (PBS) at 37◦ C. Assays of the buffer were
performed at various time steps to measure antibiotic concentration. The assays were
analyzed using Ultra Performance Liquid Chromatography tandem Mass Spectrometry
(UPLC-MS/MS). However, a sample clean up step was required before analysis could be
conducted. This project has mainly focused on the sample clean up step.
Liquid chromatography tandem mass spectrometry was chosen as the analyti-
cal method for several reasons. Tobramycin is thermally stable, and effectively non-
volatile and therefore Gas Chromatography (GC) would not be useful for analysis. With-
out distinct chromophores or fluorophores, UV-VIS spectroscopy and Fluorescence spec-
troscopy fail to identify tobramycin and vancomycin. UPLC-MS/MS not only separates
tobramycin and vancomycin, but also allows for a very low limit of quantification by
using Multiple Reaction Monitoring (MRM) Mass Spectrometry. Both antibiotics are
polar and hydrophilic, and thus required a novel column and method for separation and
chromatographic peak stability. A hydrophilic interaction chromatography (HILIC) col-
umn was chosen for its ability to retain polar analytes and use water as a strong eluent.
HILIC columns retain molecules through ion-ion interactions, adsorption, and liquid-
liquid partitioning [12]. A soft desorption ionization technique was chosen to generate
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charge on the analytes for MS detection. Positive electrospray ionization (ESI+) is a
ionization method for generating high charge-to-mass ratios for large molecules, bringing
their mass-to-charge ratios in ranges detectable by mass spectrometers. A mobile phase
with readily desolved organic solvents also aid in the charge efficiency of ESI+ [12].
A triple-quadrupole design mass spectrometer was used to further increase the
limit of quantification. The three quadrupoles are a mass analyzer, a collision chamber,
and a second mass analyzer. In the first mass analyzer, the mass-to-charge ratio of
the dominant peak (parent ion) for one analyte is selected and allowed to pass into the
collision cell. In the collision cell, the parent ion is bombarded with a stream of inert
collision gas to produce fragments. The second mass analyzer then selectively allows
the dominant fragment (daughter ion) to pass through for detection. This procedure
significantly eliminates noise from the spectrum and allows detection limits down to 500
ng/mL for both tobramycin and vancomycin. The combination of HILIC-UPLC and
MS/MS allow for the separation and quantification of two polar, hydrophilic molecules
in extremely low concentrations.
1.6 Phosphate Buffered Saline
Phosphate buffered saline (PBS) is a common buffer used to mimic physiological condi-
tions [25]. PBS effectively buffers a region of pH 7.0 ± 0.1, and contains several inorganic
salts in physiological concentrations, with a total salt concentration of 151 mM. Table 1.1
presents the concentrations of each inorganic salt.
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Table 1.1: Inorganic Salt Concentration in PBS
Inorganic Salt Concentration (g/L)
CaCl3 0.10
KCl 0.20
KH3PO4 0.20
MgCl2· 6H2O 0.10
NaCl 8.00
Na2HPO4· 7H2O 2.1716
While the presence of the inorganic salts and phosphate helps to mimic physiologi-
cal conditions, they introduce further complications for analysis. Phosphate is nonvolatile,
and precipitates out on the Mass Spectrometer when using ESI+. The high salt con-
centration, particularly sodium chloride, inhibits antibiotic quantification by forming salt
clusters during the ionization process of higher concentration than analytes. Figure 1.3
shows the spectrum obtained when a stock 10 ppm tobramycin and vancomycin in PBS
is run on the mass spectrometer using ESI+. The spectra is scaled to m/z values of
320-760, and the sodium chloride salt clusters are labeled.
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1.7 Antibiotic Extraction Methods
Several approaches have been investigated to separate the antibiotics from the phosphate
and inorganic salts of PBS. These approaches have included dialysis, liquid-liquid extrac-
tion (LLE), and solid phase extractions (SPE). Each approach has inherent advantages
and disadvantages for analyte extraction.
1.7.1 Solid Phase Extraction
Solid phase extractions are a common analytical tool for sample preparation. A typical
SPE device consists of a cartridge filled with a chromatographic packing material, also
known as the stationary phase or sorbent bed. The sample is passed through the cartridge
by vacuum filtration. Molecular interactions with the chromatographic packing material,
or sorbent bed of the cartridge, allow for the separation of the sample components. Com-
pounds with high affinities for the SPE sorbent bed are retained longer than those with
a higher affinity for the sample matrix. After the sample is passed through the cartridge,
different solvents can be used to separate the remaining compounds on the SPE sorbent
bed. The first set of solvents to follow the sample load step are called washes, and are de-
signed to remove molecules weakly bound to the sorbent bed that inhibit quantification.
Following the wash step, solvents with high affinity for the analytes of interest are passed
through the cartridge and collected to produce a simplified sample for analysis. SPE
is a very powerful technique that can be used to separate components of an analytical
mixture and reduce ion effects such as suppression or enhancement [26].
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There are many options for sorbent bed materials that allow for separations spe-
cific to molecules of interest. There are three main mechanisms for SPE separations:
reversed-phase, normal-phase, and ion-exchange. Reversed-phase and normal-phase sepa-
rations are based on polarity, whereas ion-exchange separates molecules based on electrical
charge. In reversed-phase separations, the sorbent bed is non-polar, and attracts nonpo-
lar or hydrophobic molecules. Decreasing the polarity in the eluent composition releases
the retained analyte by disrupting the analyte-sorbent bed interactions. In normal-phase
separations, the opposite is true; the sorbent bed is polar and eluent solvent strength
correlates with its polarity [27, 28].
For ion-exchange separations, charge-charge interactions drive retention and re-
lease. In polar interactions similar polarities attract one another, while in ion-exchange
similar charges repel. To retain a molecule using ion-exchange the sorbent bed can be
positively charged to attract negatively charged analytes, or the sorbent bed could be
negatively charged to attract positively charged analytes. These two mechanisms are
known as anion exchange and cation exchange, respectively [27]. Ion-exchange sorbent
beds can be further described as strong or weak. Strong ion-exchange sorbent beds have
constant charge, whereas weak ion-exchange sorbent beds can be ionized or un-ionized
depending upon the conditions of the experiment [26].
Several research groups have developed SPE methods for aminoglycosides [13–16]
or for glycopeptides[19, 29], but none to our knowledge have developed a method that
quantifies both simultaneously. Developing one method that is able to quantify both of
these chemically diverse antibiotics has been a secondary goal for this project. With this
Chapter 1. Introduction 15
goal in mind we developed full methods for several types of cartridges that are attractive
to both and vancomycin. Both tobramycin and vancomycin are polar and hydrophilic,
but tobramycin is extremely basic while tobramycin has both acidic and basic properties.
We screened three cartridges for compatibility with both analytes: Oasis Mixed-Mode
Cation Exchange (MCX), Oasis Weak-Mode Cation Exchange (WCX), and Oasis Sep-
Pak Aminopropyl (NH2) cartridge.
The Oasis MCX sorbent bed is a N-Vinylpyrrolidone-Divinylbenzene copolymer
with a sulfonic acid functional group attached to every repeating unit [26]. The sulfonic
acid group has a pKa less than 1, and was considered deprotonated for our experimental
work. The N-vinylpyrrolidone monomer is hydrophilic while the divinylbenzene monomer
is lipophilic and provides reversed-phase retention. Through the combinations of both
types of retentions the MCX cartridge works to retain molecules with basic characteris-
tics. Figure 1.4 presents the structure of the MCX sorbent bed and its interactions with
propranolol.
The Oasis WCX sorbent bed is made of the same copolymer base as MCX (N-
Vinylpyrrolidone-Divinylbenzene), but has a carboxylic acid functional group attached
instead of the sulfonic acid [26]. The charge of the sorbent bed can be controlled by
changing the pH of the solvent passing through the cartridge. The carboxylic acid group
has a pKa around 5, and therefore would be expected to be protonated when the pH
is less than 3, and deprotonated if the pH is greater than 7. Figure 1.5 presents the
structure of the WCX sorbent bed.
The Oasis Sep-Pak NH2 sorbent bed is composed of a Silica-based backbone with
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Figure 1.4: MCX sorbent bed interactions with Propranolol [26].
aminopropyl functional groups. The NH2 cartridge is characterized by moderate polarity
and its ability to attract both acidic and basic compounds mainly through reversed-phase
or normal-phase interactions, depending upon application.
1.7.2 Liquid-Liquid Extraction
Liquid-Liquid Extractions (LLEs) are another commonly used method for separating com-
ponents of a mixture. LLEs separate components based upon their partitioning between
two immiscible liquids (typically organic and aqueous liquids). When the two immiscible
liquids are mixed, they will separate by density. Solute molecules can partition between
the two phases depending on the properties of the solute. Extracting one of the phases
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Figure 1.5: WCX sorbent bed interaction with quaternary amine [26].
allows for the recovery of the solute molecules present in that phase of the solution. Shou
et al (2013) has developed a method for extracting both tobramycin and vancomycin from
human drainage tissue fluid using a multistep LLE with multiple centrifugations [30].
1.7.3 Dialysis
Dialysis effectively separates molecules in solution by their diffusion rate across a semiper-
meable membrane. For a given semipermeable membrane, solute will naturally move from
regions of high concentration to low concentration. Dialysis involves placing a sample in-
side a semipermeable chamber or vial and placing the vial inside a larger-volume buffer
solution. There are many factors that influence the flux rate of molecules across the
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membrane, including: Size, temperature, molecular shape, buffer flow outside the mem-
brane, membrane thickness and membrane pore size[31]. For our analysis we focused on
separating tobramycin and vancomycin from Phosphate and various salt clusters. van-
comycin and tobramycin are significantly larger than the Phosphate and the salt clusters,
and therefore should diffuse at a slower rate across the membrane.
Chapter 2
Experimental Methodology
2.1 Materials
The nanofibers were supplied by eSpin and were kept in sealed packaging at 4◦ C until
used for experiments. The phosphate buffered saline was purchased from Mediatech, Inc.
(Manassas, VA). The dialysis experiment utilized a Spectra/Por Float-A-Lyzer G2 model
G235027, with molecular weight cut off (MWCO) at 0.5-1.0 kiloDaltons and membrane
capacity of 1 mL. The MCX, WCX, and NH2 SPE cartridges were bought from Waters
Oasis (Milford, MA).
Fisher Optima HPLC grade acetonitrile (ACN), methanol (MeOH), and isopropyl
alcohol (IPA) were all used in creating the load, wash, and elution solvents. Concentrated
Formic acid (FA) and Ammonia (NH3) were used to control pH and for creating extraction
19
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solvents as well. Deionized MilliQ water (MQ) was used for solvents, UPLC mobile phase,
and for storing vancomycin and tobramycin.
2.2 Instrumental Parameters
Direct injection mass spectrometry (MS) scans were done exclusively on a Quattro Micro
triple-quadrupole mass spectrometer and were used to analyze the results of the SPE,
LLE, and dialysis experiments. For these acquire scans, the mass spectrometer scanned
from a m/z range of 100-800, scanning the entire range in 5 seconds, for a total time of
1 minute. With an inter-scan delay of 0.1 seconds, this allowed for 11 total scans to be
completed per acquire scan. The data was saved in Multi-Channel Analysis (MCA) mode
and was analyzed through the Waters Acquity Software Masslynx to yield MS spectra of
average intensity (counts) vs. mass-to-charge ratio. The ionization source was in positive
electrospray ionization mode (ESI+), and the MS capillary voltage and cone voltage was
set to 3.00 kV and 20 V, respectively. Analyte solution was pumped in at 10 µL/min.
The parent ion for tobramycin for quantification was set as 468.0 m/z, and repre-
sents the singly charged ion, [M + H]+. The parent ion for vancomycin was the doubly
charged ion at 725.8 m/z [M + 2H]+2. When Multiple Reaction Monitoring (MRM) was
used, the tobramycin transition from 468 m/z to 163 m/z was analyzed, while the 725.8
m/z to 144.3 m/z transition was used for vancomycin. A MS spectra with labeled peaks
for parent tobramycin and vancomycin, common cone fragments, and daughter ions is
presented in Figure 2.1
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The UPLC-MS/MS assays were done using a Waters Acquity ultra performance
liquid chromotograph interfaced with a Quattro Micro triple quadupole mass spectrom-
eter. Two mobile phases (A & B) were used to create a gradient to achieve acceptable
peak separation. Mobile phase A was 0.1% Formic Acid (FA) in MQ. Mobile phase B was
0.1% FA in ACN. The flow rate was kept to 0.4 mL/min for each experimental run, but
the mobile phase %B varied throughout to separate the molecules. The antibiotics them-
selves were stored in UPLC diluent (62:38:0.1 ACN:MQ:FA) for each analysis. The UPLC
diluent was also used to reconstitute unknowns and standards after SPE experiments.
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2.3 Nanofiber Elution
The nanofiber elution was studied by incubating nanofiber samples in PBS at 37◦ C.
Nanofiber samples were prepared by cutting 2 x 2 cm squares of nanofiber from an original
sheet provided by eSpin. The nanofiber squares were then weighed in triplicate to find
their initial mass. The initial mass was important for determining mass-loss as a function
of time as well as calculating the total amount of antibiotics expected to be present in
the nanofiber. The nanofiber square was then submerged in a Fisher Scientific test tube
filled with 10 mL of PBS that had been sitting in an incubator at 37◦ C. The sample was
then allowed to incubate inside the test tube until specified time intervals were reached.
At a time point, the PBS solution was decanted into a clean test tube and labeled with
the time point, and 10 mL of fresh PBS solution was added to the nanofiber-containing
test tube. The test tube was then placed back inside the incubating apparatus until the
next time point was reached.
2.4 Standard Preparation
Several standard solutions were used over the course of this work. While the individual
concentrations changed with each stock preparation, the procedure remained the same.
A high concentration stock solution was made by weighing respective tobramycin and
vancomycin standards and bringing them to volume in 90:10 MQ: MeOH. Relevant con-
centration working stocks were then made from the high concentration stock solution.
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The stock solutions were considered valid for 1 year when stored at 4◦ C, which is con-
sistent with several research groups who have worked with tobramycin and vancomycin
[12, 13, 19], although some groups made new stocks every 6 months [15, 16].
Chapter 3
Extraction Methods and Results
3.1 Liquid-Liquid Extraction
A liquid-liquid extraction was performed using the method outlined by Shou et al (2013)
on both a matrix of PBS and a matrix of MQ. A Fisherbrand Pipette was used to
pipette 500 µL of 20 ppm TOB and VCM stocks into a mini-centrifuge tube. The same
pipette was used to add 500 µL of acetonitrile to the mini-centrifuge tube as well. The
tubes were then vortexed for 1 minute before being placed in the mini-centrifuge for 11
minutes at 10,000 rpm. A clear pellet was observed following the first centrifugation.
The supernatant was then removed and added to 500 µL methylene chloride in another
mini-centrifuge tube and was vortexed for 1 minute. The sample was then centrifuged
again for 11 minutes at 10,000 rpm. Two distinct phases were observed following the
second centrifugation, and 200 µL of the supernatant was removed and diluted with 200
µL MQ. The diluted sample was then subjected to another round of centrifugation for
25
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11 minutes at 10,000 rpm. Approximately 100 µL of supernatant was then collected and
used to acquire a MS spectra. The observations above were noted for both the extraction
from MQ and the extraction from PBS.
Figure 3.1 presents the results of the LLE when it was done in pure MQ matrix.
The peaks at 468.4 m/z and 725.8 m/z indicate tobramycin and vancomycin recovery,
although the percent recovery was not quantified due to a standard not being run on the
same day. Figure 3.2 presents the MS scan from the LLE of 20 ppm TOB and VCM in
PBS. Unfortunately, the addition of the phosphate and salt in the matrix inhibited the
extraction as no peaks are seen at m/z values corresponding to tobramycin or vancomycin.
Chapter 3. Methods & Results 27
F
ig
u
r
e
3
.1
:
L
L
E
of
20
p
p
m
to
b
ra
m
y
ci
n
an
d
va
n
co
m
y
ci
n
fr
om
M
Q
m
at
ri
x
Chapter 3. Methods & Results 28
F
ig
u
r
e
3
.2
:
L
L
E
of
20
p
p
m
to
b
ra
m
y
ci
n
an
d
va
n
co
m
y
ci
n
fr
om
P
B
S
m
at
ri
x
Chapter 3. Methods & Results 29
3.2 Solid Phase Extractions
Solid phase extractions are simple methods for separating analytes from interfering molecules
in a solution. In this work three SPE cartridges were screened for compatibility and via-
bility with both analytes: Oasis mixed-mode cation exchange (MCX), Oasis Weak cation
exchange (WCX), and Oasis Sep-Pak aminopropyl (NH2) cartridge. Full methods for
each were developed with numerous optimization steps including optimization of solvent,
volume, and pH of the Load, Wash, and Elute steps. The methods were initially devel-
oped with standards in deionized water (MQ) matrix for the load step and then were
applied to standards in PBS for further refinement. During the experiments, the solvent
flow rate through the vacuum filtration apparatus was kept at 1-2 drops per second during
the load, wash, and elution steps to allow for kinetically slow interactions to take place.
3.2.1 MCX Cartridges
The SPE method development began with the MCX cartridges. The first series of opti-
mization experiments were conducted by Karl Green, Marcus Morgan, and Caitlin Quinn.
With both reverse-phase and strong cation-exchange interactions the MCX cartridge the-
oretically has high affinity for both tobramycin and vancomycin. During the optimization
experiments conducted by Karl Green and myself, a major problem was found in sup-
pression of analyte signals in post-spiked samples. Post-spiked samples are solutions that
undergo the entire SPE procedure, except that they do not initially have any antibiotics
in the load solution. The elute steps are collected in a test tube, dried down in a gentle
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stream of Nitrogen gas overnight, and reconstituted using the same solvent as the regular
SPE elutes, except that a known amount of antibiotics is added, providing a matrix-
matched comparison. The post-spiked samples showed lesser intensities than the same
concentration in pure UPLC diluent (62:38:0.1 ACN:MQ:FA). This inferred that the SPE
procedure failed to remove the PBS salts or was introducing new signal-inhibiting ions
and molecules.
The first set of optimization’s produced the method present in Table 3.1. Method I
ultimately failed to show consistent recovery of both antibiotics, especially when compared
with post-spiked samples.
Table 3.1: MCX SPE Method I
SPE Step Solvent Volume (mL)
Condition MeOH 1
Equilibrate MQ 1
Load PBS with TOB and VCM 1
Wash 2% FA in MQ 1
Elute 1 MeOH 1
Elute 2 5% NH3 in MeOH 1
Elute 3 90% NH3 in MeOH 1
Table 3.2 presents a method used to test the efficacy of a high ionic strength eluent:
10 mM NH4COOH (pH 4.24). The high ionic load was used to disrupt the charge-charge
interactions between the antibiotics and the sulfonic acid groups. The elution solvent
also contained some methanol to disrupt the reverse-phased interactions between the
antibiotics and the N-Vinylpyrrolidone.
The load, wash, and elute steps were collected, dried down in a gentle stream
of Nitrogen gas, and reconstituted in UPLC diluent (62:38:0.1 ACN:MQ:FA). Direct
injection MS scans were acquired on both Elute 1 (E1) and Elute 2 (E2). The spectra
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Table 3.2: MCX SPE Method II
SPE Step Solvent Volume (mL)
Condition MeOH 1
Equilibrate MQ 1
Load 50 ppm TOB & VCM in PBS 1
Wash MQ 1
Elute 1 MeOH 1
Elute 2 80:20 (10 mM NH4COOH):(MeOH) 1
Elute 3 20:80 (10 mM NH4COOH):(MeOH) 1
are presented in Figures 3.3 and 3.4, respectively. The spectra show several distinct m/z
peaks, however, none that correspond to m/z values of tobramycin or vancomycin. The
m/z peak pattern in Figures 3.3 and 3.4 are separated by masses of approximately 68 amu,
and represent a clustering of NaCOOH in the sample. This is particularly interesting
considering the eluent used for the extraction was ammonium formate (NH4COOH),
implying that despite the extraction procedure a significant amount of sodium was left
in the sample.
3.2.2 WCX Cartridge
The WCX cartridge utilizes reverse-phase interactions and weak cation exchange retention
mechanisms, where the charge of the sorbent bed can be modified by solvent pH. Several
load solvent, wash solvent, and elution solvents have been tested for compatibility for
tobramycin and vancomycin.
Initial method development with the WCX cartridges optimized the procedure
found in Table 3.3. The method used 2% FA in 60:40 ACN:MeOH to recover vancomycin
(E1) and 5% NH3 in MQ to recover tobramycin (E2). Two separate 1 mL portions of
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E2 were run through the cartridge (labeled E2a and E2b) and analyzed to examine the
volume of solvent needed to pull tobramycin from the sorbent bed.
Table 3.3: WCX SPE Method I
SPE Step Solvent Volume (mL)
Condition MeOH 1
Equilibrate MQ 1
Load 20 ppm TOB & VCM in PBS 1
Wash MQ 1
Elute 1 2% FA in 60:40 ACN:MeOH 1
Elute 2a 5% NH3 in MQ 1
Elute 2b 5% NH3 in MQ 1
The load, wash, and elute steps were collected for MS analysis, dried down overnight
using a gentle Nitrogen gas stream, and reconstituted in 1 mL of UPLC diluent (62:38:0.1
ACN:MQ:FA). The MS spectra acquired for the wash and load steps are shown in Figure
3.5, while MS spectra of Elute 1 (E1) and Elute 2a (E2a) are shown in Figure 3.6.
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It was observed that Method I worked fairly well with analytes in a pure MQ
matrix, but started to fail during the transition of the method to pure PBS matrix.
The following study was conducted to observe the point at which Method I started to
lose its efficacy. The same procedure outlined in Table 3.6 was used, however the load
concentrations of tobramycin and vancomycin were increased to 50 ppm and the percent
PBS in the load was altered for several permutations. The exact permutations used
are displayed in Table 3.4 below. The MS spectra of the 100% PBS and 0% PBS load
solutions are shown in Figure 3.7. The MS spectra of the collected wash steps of the 0%
PBS and 100% PBS load solutions are shown in Figure 3.8 below. In both Figure 3.7 and
3.8, neither tobramycin or vancomycin m/z signals were present, inferring that they are
retained regardless of the presence of PBS. Figure 3.9 presents the intensity of tobramycin
and vancomycin recovery as a function of percent PBS in the load solution for Elute 1.
Figure 3.10 presents the intensity of tobramycin and vancomycin recovery as a function
of percent PBS in the load solution for Elute 2.
Table 3.4: WCX Load Solvents for Percent PBS in Load Study
Load TOB & VCM Concentration (ppm) Percent PBS in Load Solvent (%)
50 0
50 10
50 30
50 50
50 70
50 100
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Figure 3.9: WCX SPE Method I Percent PBS in Load Study Elute 1
Figure 3.10: WCX SPE Method I Percent PBS in Load Study Elute 2
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Table 3.5 describes a method using a high ionic-strength buffer to elute the antibi-
otics from the WCX cartridge. The pH of the 10 mM NH4COOH was measured using a
pH meter and was recorded as 4.24 before the solvents were made. The high ionic load
aimed to disrupt the charge-charge interactions between the antibiotics and the sorbent
bed.
Table 3.5: WCX SPE Method II
SPE Step Solvent Volume (mL)
Condition MeOH 1
Equilibrate MQ 1
Load 50 ppm TOB & VCM in PBS 1
Wash MQ 1
Elute 1 80:20 (10 mM NH4COOH):(MeOH) 1
Elute 2 20:80 (10 mM NH4COOH):(MeOH) 1
MS spectra were collected for both Elute 1 (E1) and Elute 2 (E2), and are presented
below as Figure 3.11 and Figure 3.12, respectively.
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Figure 3.11 shows the MS scan of Elute 1. The spectra contains the same sodium
formate cluster pattern (NaCOOH) as MCX E1 and E2 from Figures 3.3 and 3.4 on
page 32, but no apparent tobramycin or vancomycin recovery. The MS scan of E2 is pre-
sented in Figure 3.12, and shows significant noise throughout the spectra. No tobramycin
was found in the MS scan, although vancomycin was found (Figure 3.12 insert) with an
intensity of 2.77 × 107 counts.
Chapter 3. Methods & Results 44
F
ig
u
r
e
3
.1
2
:
W
C
X
S
P
E
M
et
h
o
d
II
E
lu
te
2
Chapter 3. Methods & Results 45
3.2.3 NH2 Cartridge
Sep-Pak aminopropyl (NH2) cartridges are typically used for hydrophilic molecules. With
the polar and hydrophilic nature of both tobramycin and v ancomycin, the NH2 cartridge
is a good candidate for retaining both analytes. Nine individual SPE methods have been
tested thus far, including a study on the effect of load pH (Method VI), load percent PBS
(Method VII), and two studies on the effects of diluting the load solution with organic
or aqueous solvents (Method V and Method IX). All studies on the NH2 cartridges have
been performed with pre-spiked standard solutions for the purpose of knowing how much
should be recovered.
Method I for the NH2 cartridge is presented in Table 3.6. The load solution was
made by pipetting 1 mL of 10 ppm TOB & VCM in PBS standard into 3 mL of ACN. The
high organic content of the load caused precipitates to crash out of solution. The load
was centrifuged for 10 minutes and the supernatant loaded onto the SPE cartridge and
underwent the procedure. Method I showed no recovery of tobramycin or vancomycin in
either Elute 1 or Elute 2.
Table 3.6: NH2 SPE Method I
SPE Step Solvent Volume (mL)
Condition 75:25 ACN:MQ 0.5
Equilibrate 75:25 ACN:MQ 0.5
Load 1:3 (10 ppm TOB & VCM in PBS):ACN 4
Wash 75:25 ACN:MQ 1
Elute 1 50:50:1 ACN:MQ:FA 1
Elute 2 25:75:1 ACN:MQ:FA 1
Table 3.7 presents NH2 SPE Method II. After 1 mL 10 ppm TOB & VCM in PBS
was pipetted into 5 mL ACN precipitates were observed crashing out. The load solution
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was centrifuged and the supernatant extracted for the SPE procedure. Unfortunately
Method II did not recover any tobramycin or vancomycin in Elute 1, and the wash step
was collected and did not have traces of analyte either.
Table 3.7: NH2 SPE Method II
SPE Step Solvent Volume (mL)
Condition MeOH 1
Equilibrate MQ 1
Load 1:5 (10 ppm TOB & VCM in PBS):ACN 6
Wash 90:10 ACN:MQ 1
Elute 1 10:90:1 ACN:MQ:FA 1
NH2 Method III, presented in Table 3.8, was the first in a series of methods that
focused on optimizing an NH2 SPE method in MQ before applying it to a solution of
PBS. Elute 1 recovered small amounts of both tobramycin and vancomycin, although a
standard was not run on that day so as to determine the percent recovery.
Table 3.8: NH2 SPE Method III
SPE Step Solvent Volume (mL)
Condition MeOH 1
Equilibrate MQ 1
Load 1:3 (10 ppm TOB & VCM in MQ):ACN 4
Wash 75:25 ACN:MQ 1
Elute 1 25:75:1 ACN:MQ:FA 1
For NH2 Method IV, a different stock solution than the previous solutions was
used. The key change for this method was to investigate the effects of lessening the
aqueous-to-organic solvent ratio in the load step. The change in the load step was incon-
clusive in positively or negatively effecting antibiotic recovery. Method IV is presented in
Table 3.9
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Table 3.9: NH2 SPE Method IV
SPE Step Solvent Volume (mL)
Condition MeOH 1
Equilibrate MQ 1
Load 1:1 (10 ppm TOB & VCM in MQ):ACN 2
Wash 75:25 ACN:MQ 1
Elute 1 25:75:1 ACN:MQ:FA 1
NH2 Method V is the application of NH2 Method IV to a standard solution of
tobramycin and vancomycin in PBS instead of MQ. Another change was the addition of
a second elute fraction of the same solvent as Elute 1. The purpose of this addition was
to test if 1 mL of elution solvent was capturing all of the analytes. Unfortunately, this
method failed to recover either tobramycin or vancomycin in either elute.
Table 3.10: NH2 SPE Method V
SPE Step Solvent Volume (mL)
Condition MeOH 1
Equilibrate MQ 1
Load 1:1 (10 ppm TOB & VCM in PBS):ACN 2
Wash 75:25 ACN:MQ 1
Elute 1 25:75:1 ACN:MQ:FA 1
A load step study on the effect of diluting the initial load sample with MQ, ACN,
or a combination of the two was performed and used Method V. The composition of the
load solutions investigated are presented in Table 3.11. The 1:9:2 (10 ppm TOB & VCM
in PBS):ACN:MQ was made by pipetting 1 mL of 10 ppm TOB & VCM in PBS into a
test tube and then pipetting 9 mL ACN followed by 2 mL of MQ. The 1:6:1 (10 ppm TOB
& VCM in PBS):ACN:MQ was made by pipetting 1 mL of 10 ppm TOB & VCM in PBS
into a test tube and then pipetting 6 mL of ACN followed by 2 mL of MQ. The 1:0:0 (10
ppm TOB & VCM in PBS):ACN:MQ was simply made by pipetting 1 mL of 10 ppm TOB
& VCM in PBS into a test tube. The 1:0:4 (10 ppm TOB & VCM in PBS):ACN:MQ was
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made by pipetting 1 mL 10 ppm TOB & VCM in PBS into 4 mL of MQ. After each load
solution was made they were vortexed for 30 seconds before loading. The load, wash, and
elute steps were collected and run on the mass spectrometer. Figures 3.13- 3.15 present
the load, wash, and elute MS scans, respectively. Neither analyte was observed in the
load or wash steps. A sodium adduct of tobramycin with a m/z of (TOB + Na)+ was
observed in L1 and L2 of Figure 3.15 though, indicating some tobramycin recovery that
increased as the load volume increased.
Table 3.11: WCX Load Solvents for Percent PBS in Load Study
Load Number 10 ppm TOB & VCM in PBS (mL) ACN (mL) MQ (mL)
1 1 9 2
2 1 6 1
3 1 0 0
4 1 0 4
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NH2 Method VI utilized the elution solvent used by Kaufmann et al (2012) at two
different pH values for our elution. The elution solution was made by dissolving 6.33208
grams ammonium formate (NH4HCO2) in 70 mL MQ and 20 mL ACN. The solution was
then quantitatively transferred to a 100 mL volumetric flask and brought to volume. The
initial pH of the solution was measured to be 6.02. Part of the solution (50 mL) was then
transferred to a separate bottle, and concentrated Ammonia NH3 was added drop-wise
until the pH was 9.07. The pH 6.02 ammonium formate solution was used for Elute 2
and the pH 9.07 solution was used for Elute 3. Three pH value 10 ppm TOB and VCM
in MQ load solutions were prepared for the study; a pH 1.9, 3.9, and 5.8, which were all
made by adding concentrated FA to 1 mL 10 ppm TOB and VCM in MQ stock solutions
until the pH was reached. Table 3.12 presents the SPE method, while Table 3.13 presents
the load permutations examined.
Table 3.12: NH2 SPE Method VI
SPE Step Solvent Volume (mL)
Condition/equilibrate 75:25 ACN:MQ 1
Load See Table 3.13 1
Wash MQ 1
Elute 1 MeOH 1
Elute 2 Kaufmann eluent pH 6.02 1
Elute 3 Kaufmann eluent pH 9.07 1
Table 3.13: NH2 SPE Method VI Load Solvents
Solvent Volume (mL) pH
10 ppm TOB & VCM in MQ 1 1.9
10 ppm TOB & VCM in MQ 1 3.9
10 ppm TOB & VCM in MQ 1 5.8
Method VII worked to study the effect of PBS in the load solution. Previous
SPE methods were recovering both analytes successfully when the load solution was
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a pure MQ matrix, however, the same methods failed tremendously when applied to
solutions of pure PBS. The study aimed at creating a gradient of percent PBS in a 50
ppm tobramycin and vancomycin load solution to observe the point where the eluents
failed to work. Table 3.14 presents the SPE method while Table 3.15 presents the load
permutations. After the 25:75:1 ACN:MQ:FA eluents were passed through the cartridge,
1 mL of MeOH was run through preceding a high ionic strength 25 mM ammonium
acetate (CH3COONH4) eluent.
Table 3.14: NH2 SPE Method VII
SPE Step Solvent Volume (mL)
Condition/equilibrate 75:25 ACN:MQ 1
Load See Table 3.15 1
Wash 75:25 ACN:MQ 1
Elute 1 25:75:1 ACN:MQ:FA 1
Elute 2 25:75:1 ACN:MQ:FA 1
Elute 3 MeOH 1
Elute 4 25 mM CH3COONH4 1
Table 3.15: WCX Load Solvents for Percent PBS in Load Study
Load TOB & VCM Concentration (ppm) Percent PBS in Load Solvent (%)
50 0
50 10
50 30
50 50
50 70
50 100
The results were very fascinating to examine. The load, wash, elute-1 (E1) and
elute-2 (E2) steps were collected and MS spectra acquired. The results of each step are
presented in Figures 3.16- 3.19.
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Figure 3.16: NH2 Method VII Percent PBS in Load Load-step Analyte Breakthrough
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Figure 3.17: NH2 Method VII Percent PBS in Load Wash-step Analyte Breakthrough
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Figure 3.18: NH2 Method VII Percent PBS in Load Elute 1 Recovery.
Chapter 3. Methods & Results 57
Figure 3.19: NH2 Method VII Percent PBS in Load Elute 2 Recovery.
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Method VIII utilized a high ionic-load eluent to try to remove tobramycin and
vancomycin from the sorbent bed. Two permutations of elutes were made with 10 mM
ammonium formate (NH4HCO2) and MeOH. A 80:20 (10 mM NH4COOH):MeOH eluent
was made by pipetting 8 mL of 10 mM NH4HCO2 into a test tube and adding 2 mL
of MeOH. A 20:80 (10 mM NH4COOH):MeOH was made by pipetting 2 mL of 10 mM
NH4COOH into a test tube and adding 8 mL of MeOH.
Table 3.16: NH2 SPE Method VIII
SPE Step Solvent Volume (mL)
Condition/equilibrate 75:25 ACN:MQ 1
Load See Table 3.15 1
Wash 75:25 ACN:MQ 1
Elute 1 25:75:1 ACN:MQ:FA 1
Elute 2 25:75:1 ACN:MQ:FA 1
Elute 3 MeOH 1
Elute 4 25 mM CH3COONH4 1
While NH2 Method V (Table 3.10 on page 47) investigated the effects of diluting
the PBS load solution with ACN and MQ, the organic-to-aqueous ratio of the load never
surpassed 3:1. Method IX studied the effects of increasing the ratio of organic to aqueous
solvent in the load solution up to 14:1, while also including a 9:1 and a 5:1 organic:aqueous
ratio load. The 5:1 ACN:(20 ppm TOB and VCM in PBS) was made by pipetting 1 mL
of 20 ppm TOB and VCM in PBS into 5 mL of ACN. The 9:1 ACN:(20 ppm TOB and
VCM in PBS):ACN was made by pipetting 1 mL of 20 ppm TOB and VCM in PBS
into 9 mL of ACN. The 14:1 ACN:(20 ppm TOB and VCM in PBS):ACN was made by
pipetting 1 mL of 20 ppm TOB and VCM in PBS into 14 mL of ACN. Each load solution
was then centrifuged for 10 minutes. The supernatant was then loaded onto the SPE
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cartridge for analysis. Table 3.17 presents the procedure and solvents of NH2 Method
IX, and Table 3.18 presents the load permutations used.
Table 3.17: NH2 SPE Method IX
SPE Step Solvent Volume (mL)
Condition/equilibrate MeOH 1
Equilibrate MQ 1
Load See Table 3.18 1
Wash 75:25 ACN:MQ 1
Elute 1 25:75:1 ACN:MQ:FA 1
Elute 2 20:80 (10 mM NH4COOH):(MeOH) 1
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Table 3.19: Summary of NH2 Elution Solvents Used
Solvent Volume (mL) pH
50:50:1 ACN:MQ:FA 1 N/A
25:75:1 ACN:MQ:FA 1 N/A
10:90:1 ACN:MQ:FA 1 N/A
Kaufmann pH 6.02 eluent 1 6.02
Kaufmann pH 9.06 eluent 1 9.07
25 mM CH3CHOONH4 1 N/A
80:20 (10mM NH4COOH):MeOH 1 4.0*
20:80 (10mM NH4COOH):MeOH 1 4.0*
2% FA in MQ 1 N/A
10 mM NH4COOH 1 4.0
2% NH3 in MQ 1 N/A
* pH of 4.0 refers to 10mM NH4COOH before MeOH was added
3.3 Dialysis Experiment
To begin the dialysis experiment, 500 µL of 200 µg/mL TOB stock and 500 µL of 200
µg/mL VCM stock was pipetted into a Fisher Scientific test tube, mixed, and dried down
under a gentle stream of Nitrogen gas. The analytes were then reconstituted in 1 mL of
UPLC diluent (62:38:0.1 ACN:MQ:FA), and a direct injection MS scan was acquired on
45 µL of the 100 µg/mL TOB and VCM in PBS solution. The scan was used to ensure
the antibiotics were still stable, and as a psuedo-comparison for calculating antibiotic
recovery. The solution was then dried down again before being reconstituted in 1 mL of
PBS.
The Float-A-Lyzer 2 (FAL2) dialysis membrane was first wetted in 10:90 IPA:MQ
for 10 minutes in a 150 mL beaker. After wetting, the membrane was conditioned with
pure MQ by pipetting 1 mL of MQ into the membrane and placing the membrane in
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200 mL of MQ in a 400 mL beaker. A 1000 mL beaker was then filled to the 800 mL
mark with MQ, and a stir bar was placed at the bottom to stir the solution. The FAL2
was then removed from the MQ conditioning beaker and 1 mL of 100 µg/mL tobramycin
and vancomycin in PBS was loaded into the membrane. The buffer solution (MQ) was
changed after 2.5 hrs, 4.7 hrs, 19.9 hrs, and after 28 hours. An 8 mL assay of buffer
solution was collected before each buffer change to test for antibiotic breakthrough. The
recovered sample from the FAL2 was then extracted using a pipette, and was dried down
using a gentle Nitrogen gas stream before further analysis. The sample was reconstituted
in 1 mL of UPLC diluent (62:38:0.1 ACN:MQ:FA) before a direct injection MS acquire
scan was run. The MS spectra is presented in Figure 3.20, below.
Chapter 3. Methods & Results 63
F
ig
u
r
e
3
.2
0
:
D
ia
ly
si
s
E
x
p
er
im
en
t
A
n
al
y
te
R
ec
ov
er
y
Chapter 3. Methods & Results 64
Tobramycin and vancomycin were clearly recovered by the presence of resolved
peaks at 468.2 m/z and 725.4 m/z. However, when their intensity in counts was compared
to a 100 ppm standard in the UPLC diluent (62:38:0.1 ACN:MQ:FA), only 5.6% of
tobramycin and 16.0% of vancomycin were recovered. With that being said, the standard
for comparison was run on a different day, so a method-accurate determination was not
available. Mass spectrometry scans of the buffers were also acquired, and are presented
in Figures 3.21- 3.24.
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The first and second buffers contained a large number of salt clusters. The third
and fourth buffer had considerably cleaner spectra throughout the regions where to-
bramycin and vancomycin are expected.
Chapter 4
Discussion and Future Direction
The recovery process for patients suffering from traumatic bone injury can be very ardu-
ous. A common complication is infection in the weeks after the operation when the bone
is in a critical state of recovery. While there are medical devices currently available to
impede infection from taking root, many suffer drawbacks including non-uniform antibi-
otic release as well as a second operation to extract the device from the body. The drug
delivery device of this thesis offers a plethora of advantages over many current methods.
Namely, controlling antibiotic release rate for maximum efficacy, providing structural sup-
port by wrapping around the healing bone, and negating a second surgery by degrading
into biocompatible components.
Optimization of nanofiber spin parameters to change the release rate of antibiotics
relies on an accurate method to quantify the antibiotic release rate as a function of time.
The work of this thesis has mainly focused on developing a method to determine the
elution rate while in a physiologically relevant matrix. The phosphate buffered saline
70
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(PBS) contains several ions and molecules that inhibit detection using UPLC-MS/MS,
and samples required a clean-up step before analysis could be conducted.
Several extraction methods were developed to determine their possible efficacy
for separating tobramycin and vancomycin from the phosphate and inorganic salts in
PBS. These included dialysis, liquid-liquid extraction, and several types of solid phase
extractions.
The dialysis effectively cleaned the final sample of all Phosphate and inorganic
salts, however only a small fraction of the antibiotics were retained. While samples
of the buffer solutions were run to observe when tobramycin and vancomycin diffused
through the membrane, their high volumes (800 mL) would have required a significantly
higher concentration to get into our limit of detection. Advantages of the dialysis method
include not having to introduce the sample to any other solvents other than the UPLC
diluent for UPLC-MS/MS analysis. Not only does this conserve chemical solvents, it also
limits opportunities for degradation of the antibiotics or introduction of molecules that
inhibit separation on UPLC or detection using MS/MS. A possible future direction for
this method is to use a dialysis membrane with a smaller pore size. Diffusion across the
membrane slows as membrane pore size decreases, adding time to each experiment, but
with the possibility of retaining more tobramycin and vancomycin. Also, using a smaller
buffer size would enable determination of when tobramycin and vancomycin diffused
across the membrane, and if the analytes could be extracted in between the period when
the salts diffuse across the membrane and the analytes start to permeate through.
The liquid-liquid extraction method from Shou et al was already designed for
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extracting tobramycin and vancomycin. However, it was adapted in a different matrix.
This work examined the procedure on a standard sample in MQ and a standard sample in
PBS while Shou et al completed their extraction in drainage tissue fluid [30]. The standard
in MQ produced a MS spectra with clear m/z peaks for tobramycin and vancomycin.
Unfortunately, when the procedure was adapted for the standard in PBS, salt clusters
had replaced the analyte peaks. The simplicity and speed of LLEs are a major positive
factor for future development. Future work could aim at examining the effect of pH
on extraction efficiency, as the buffered pH of the PBS might have produced a different
charged state for the antibiotics than the pure MQ matrix.
Three SPE cartridges with different selectivity were screened for effectiveness ex-
tracting tobramycin and vancomycin: Mixed-Mode Strong Cation Exchange (MCX),
Weak Cation Exchange (WCX), and a Sep-Pak aminopropyl (NH2) cartridge.
The methods with the MCX cartridge suffered from several major flaws. No elution
solvent was found that would effectively remove tobramycin and vancomycin from the
cartridge sorbent bed without introducing new matrix effects that inhibit quantification.
The WCX and NH2 cartridges had much more success in finding ways to extract the
analytes in ways that could be analyzed using UPLC-MS/MS.
The WCX cartridge SPE methods had mixed success. Most notably was Method
I, where Elute 2 (5% NH3 in MQ) consistently extracted tobramycin from the sorbent bed
regardless of percent PBS in load. An elution solvent (E1, 2% FA in 60:40 ACN:MeOH)
was also developed for the exclusive extraction of vancomycin, although it was not nearly
as effective as E2 was for tobramycin and failed to extract vancomycin after 30% of the
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load solution was PBS. There was an idea for collecting both elution solvents into one test
tube for simultaneous quantification, however, the 5% NH3 in MQ eluent had devastating
effects on vancomycin signal intensity. Figure 4.1 presents a standard 3 ppm solution of
both tobramycin and vancomycin in 5% NH3 in MQ matrix. The MS spectrum is scaled
to the m/z range of 320-765.
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Further studies were conducted on the WCX cartridge past Method I, however
none succeeded in retrieving both tobramycin and vancomycin quantifiably. Future work
could investigate the pH of load and elution solvents more extensively and systematically.
The NH2 cartridge presented the best case among the SPE cartridges for future
efficacy and has been the SPE focus for the past year. Method IV was the first method
that found a solvent that extracted both tobramycin and vancomycin simultaneously.
Several studies were conducted to survey the effects of diluting the load sample with
organic and aqueous solvents. The percent PBS in the Load Step study (Method VII)
showed that recovery of some tobramycin and vancomycin is possible up until 50% of
the load solution is PBS. Surprisingly, the study also inferred that the addition of PBS
actually started to aid in analyte retention on the column, as the antibiotic breakthrough
lessened as the percent PBS in the load increased. Future experiments could aim at finding
a compromise that maximizes retention on the sorbent bed during the load and wash
steps and extraction from sorbent bed during the elution. This could be further aided in
further development of stronger eluents for retrieving the analytes from the sorbent bed.
Method VIII utilized a strong ionic load eluent that recovered some analytes, but further
development and comparison experiments are needed to determine if it outperforms the
elution solvents of Method VII.
There is significant room for progress with all methods for extraction, although
some might prove to be more effective than others. This work effectively surveyed the
possible extraction methods and laid a basis for future directions of extracting both
tobramycin and vancomycin from phosphate buffered saline. The foundation set in place
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will allow for further development of an effective method for quantifying the rate of
antibiotic release from nanofibers as a function of time.
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